Beacon Biosignals Raises $27M in Series A


Beacon Biosignals, a Boston MA-based neurotechnology company, raised $27M in Series A funding.

The round, which brought Beacon Biosignals’ total funding to date to $30m, was led by General Catalyst and with participation from Casdin Capital. As part of the deal, Robin Washington will join Beacon Biosignals’ board of directors. Robin was previously CFO at Gilead and currently holds board seats at Alphabet (the parent company of Google), Salesforce and Honeywell.

The company intends to use the funds to:

  • scale its computational biomarker discovery platform,
  • address the need for quantitative clinical trial endpoints, safety tools, and computational diagnostics for neurology, psychiatry, and sleep medicine, and
  • pursue new partnerships with leading pharma and biotech companies, and build on existing partnerships with Novartis, Praxis Precision Medicines, Cyclerion Therapeutics, Idorsia and other undisclosed leading biopharma and operational partners.

Founded in 2019 by MD/PhDs and engineers from Harvard and MIT, and led by Jacob Donoghue MD, PhD and CEO, Beacon is applying artificial intelligence to EEG (electroencephalography) to unlock precision medicine for any condition affecting the brain. The company’s platform enables and accelerates treatments for patients with neurological, psychiatric or sleep disorders through novel machine learning algorithms, large datasets, and advances in software engineering.